MA-PERKINELMER
Horizon Discovery Extends Gene Modulation Portfolio with Industry First Synthetic Single Guide RNA and Patent Pending dCas9 Repressor for CRISPR Interference
Horizon Discovery, a PerkinElmer, Inc. (NYSE:PKI) company, today announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional level, ultimately leading to new therapeutic approaches.
The new reagents include the first-ever commercially available synthetic single guide RNAs for CRISPRi , as well as a patent-pending, dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. With these new technologies, researchers will have the flexibility to repress genes in almost all cell lines, over any length of time, and at any scale from single gene readouts to high-throughput studies.
The novel dCas9-SALL1-SDS3 repressor was developed following extensive research and has shown more robust and consistent gene modulation over a longer course of time compared to current-generation CRISPRi products.
Alan Fletcher, SVP Life Sciences at PerkinElmer said, “CRISPRi is gene knockdown, not knockout. It’s CRISPR without the cut, so it offers a temporary and nuanced approach which is ideal for researchers looking to mimic cellular effects of small molecule drugs or do multiplexed gene interrogation. By offering these new reagents, in addition to our existing CRISPR options, we’re primed to aid researchers in achieving even more exciting breakthroughs in the years ahead.”
Horizon Discovery’s Dharmacon technology, with its patented siRNA tools, has been the market leader in gene modulation for more than 20 years. Since the discovery of CRISPR gene editing tools, Horizon has been on the forefront offering guide and nuclease products to enable precision DIY CRISPR knockout and knock-in as well as custom screening and cell line production services. CRISPRmod CRISPRi continues the tradition of innovation by developing novel CRISPR-based transcriptional gene modulation reagents. Portfolio-wide, Horizon helps researchers answer fundamental biological questions leading to therapeutic advancements.
For further information on Horizon Discovery’s CRISPRi technology, please visit: https://horizondiscovery.com/en/applications/crisprmod/crispri .
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at https://www.perkinelmer.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BOLLÉ-SAFETY16.4.2021 22:02:13 CEST | Press release
Advanced Eye Protection Against Covid-19 For Healthcare Professionals – an Exclusive Bollé Safety Technology
ZEEPAY16.4.2021 19:57:10 CEST | Press release
Zeepay Ghana Acquires Mangwee Mobile Money in Zambia
CGTN16.4.2021 18:31:06 CEST | Press release
CGTN: Leading With Action: China in the Fight for Carbon-Neutral Future
NY-COLICITY-INC16.4.2021 15:32:08 CEST | Press release
Colicity Inc. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about April 16, 2021
MERCK16.4.2021 10:02:11 CEST | Press release
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
NY-IFF15.4.2021 22:17:49 CEST | Press release
IFF Presents “Learning Labs” Video Series to Demonstrate Potential of New Company
MA-BRIDGETOWER-CAPITAL15.4.2021 22:16:09 CEST | Press release
Algorand and BridgeTower Capital Announce Strategic Partnership
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom